Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

I Roos; S Sharmin; C Malpas; S Ozakbas; J Lechner-Scott; S Hodgkinson; R Alroughani; S Eichau Madueño; C Boz; A van der Walt; H Butzkueven; K Buzzard; O Skibina; M Foschi; F Grand’Maison; N John; P Grammond; M Terzi; J Prévost; M Barnett; G Laureys; L Van Hijfte; J Luis Sanchez-Menoyo; Y Blanco; J Oh; P McCombe; C Ramo Tello; A Soysal; A Prat; P Duquette; BI Yamout; S Khoury; V van Pesch; R Macdonell; M José Sá; M Slee; J Kuhle; D Maimone; DLA Spitaleri; B Willekens; AA Asmi; E Tallantyre; NP Robertson; A Coles; JW L Brown; T Kalincik

Journal article

Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

I Roos, S Sharmin, C Malpas, S Ozakbas, J Lechner-Scott, S Hodgkinson, R Alroughani, S Eichau Madueño, C Boz, A van der Walt, H Butzkueven, K Buzzard, O Skibina, M Foschi, F Grand’Maison, N John, P Grammond, M Terzi, J Prévost, M Barnett Show all

Multiple Sclerosis Journal | Published : 2024

DOI: 10.1177/13524585241267211

Download PDF

Abstract

Background: Comparisons between cladribine and other potent immunotherapies for multiple sclerosis (MS) are lacking. Objectives: To compare the effectiveness of cladribine against fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting MS. Methods: Patients with relapsing-remitting MS treated with cladribine, fingolimod, natalizumab, ocrelizumab or alemtuzumab were identified in the global MSBase cohort and two additional UK centres. Patients were followed for ⩾6/12 and had ⩾3 in-person disability assessments. Patients were matched using propensity score. Four pairwise analyses compared annualised relapse rates (ARRs) and disability outcomes. Results: The eligible cohorts..

View full abstract

University of Melbourne Researchers

Izanne Roos Author

Sifat Sharmin Author

Charles Malpas Author

Richard MacDonell Author

Related Projects (4)

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

BIOMARKERS TO PREVENT DISABILITY IN MULTIPLE SCLEROSIS

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

Personalised therapy to prevent disability in aggressive multiple sclerosis

Grants

Awarded by Queen Elisabeth Medical Foundation

Funding Acknowledgements

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the NHMRC (grant nos. 2026836). IR is supported by a MS Australia postdoctoral fellowship grant. The MSBase Foundation is a not-for-profit organisation that receives support from Biogen, Novartis, Merck, Roche, Teva and Sanofi Genzyme. Design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript and decision to submit the manuscript for publication were conducted separately and apart from the guidance of the sponsors.